DAB2IP and prostate cancer: In a study published in 2010, Kong Z and colleagues presented evidence suggesting that DAB2IP-deficient prostate cancer cells that have metastasized show greater clonogenic survival when treated with ionizing radiation than control cells expressing normal levels by DAB2IP.